Home
IOBT
IOBT News

Latest IO Biotech Inc. (IOBT) News on November 25, 2025

IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why

Zacks

6 days ago

IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire

11 days ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire

13 days ago

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire

18 days ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MT Newswires

6 months ago

IO Biotech Regains Compliance With Nasdaq Listing Rules

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

6 months ago

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

GlobeNewswire

6 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

IO Biotech price target raised to $14 from $12 at H.C. Wainwright

TipRanks

6 months ago

IO Biotech price target raised to $14 from $12 at H.C. Wainwright

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire

6 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

GlobeNewswire

7 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

GlobeNewswire

7 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Simply Wall St.

7 months ago

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

8 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025

GlobeNewswire

8 months ago

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025

IO Biotech Reports 2024 Business Highlights

GlobeNewswire

9 months ago

IO Biotech Reports 2024 Business Highlights

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

GlobeNewswire

9 months ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

GlobeNewswire

9 months ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

GlobeNewswire

10 months ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech enrols all subjects in Phase II trial of cancer combination therapy

Clinical Trials Arena

10 months ago

IO Biotech enrols all subjects in Phase II trial of cancer combination therapy

MT Newswires

a year ago

IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

GlobeNewswire

a year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

GlobeNewswire

a year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

GlobeNewswire

a year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire

a year ago

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

GlobeNewswire

a year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire

a year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

GlobeNewswire

a year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

IO Biotech’s melanoma treatment trial to continue after IDMC review

Clinical Trials Arena

a year ago

IO Biotech’s melanoma treatment trial to continue after IDMC review

MT Newswires

a year ago

IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

GlobeNewswire

a year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire

a year ago

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

GlobeNewswire

a year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

GlobeNewswire

a year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

IO Biotech, Inc.'s (NASDAQ:IOBT) market cap touched US$104m last week, benefiting both private equity firms who own 59% as well as institutions

Simply Wall St.

a year ago

IO Biotech, Inc.'s (NASDAQ:IOBT) market cap touched US$104m last week, benefiting both private equity firms who own 59% as well as institutions

Will IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?

Simply Wall St.

a year ago

Will IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?

IO Biotech to Present at Jefferies Global Healthcare Conference

GlobeNewswire

2 years ago

IO Biotech to Present at Jefferies Global Healthcare Conference

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

GlobeNewswire

2 years ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire

2 years ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

GlobeNewswire

2 years ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

GlobeNewswire

2 years ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

GlobeNewswire

2 years ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

GuruFocus.com

2 years ago

IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

2 years ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

GlobeNewswire

2 years ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

IO Biotech to Present at 44th Annual Cowen Health Care Conference

GlobeNewswire

2 years ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Kopin Receives $3 Million in New Orders for Several Simulated Thermal Sights

Business Wire

2 years ago

Kopin Receives $3 Million in New Orders for Several Simulated Thermal Sights

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Universal Stainless & Alloy Products Inc Earnings Call

Associated Press Finance

2 years ago

The First Bancorp Inc.: Q4 Earnings Snapshot

Business Wire

2 years ago

The First Bancorp Reports Results for 2023

GuruFocus.com

2 years ago

Universal Stainless & Alloy Products Inc (USAP) Reports Record Sales in Q4 2023

Universal Stainless Business Update Call and Webcast Scheduled for Today, January 24th

GlobeNewswire

2 years ago

Universal Stainless Business Update Call and Webcast Scheduled for Today, January 24th

Chuck Royce Adjusts Position in Hurco Companies Inc

GuruFocus.com

2 years ago

Chuck Royce Adjusts Position in Hurco Companies Inc

American Battery Technology Company Announces Increased and Upgraded Lithium Resource to Measured and Indicated Classifications for One of the Largest Lithium Projects in the United States

PR Newswire

2 years ago

American Battery Technology Company Announces Increased and Upgraded Lithium Resource to Measured and Indicated Classifications for One of the Largest Lithium Projects in the United States

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

GlobeNewswire

2 years ago

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

Allbirds looks to sports veterans for chief marketing, design roles

Retail Dive

2 years ago

Allbirds looks to sports veterans for chief marketing, design roles

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

PR Newswire

2 years ago

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

Simply Wall St.

2 years ago

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

Bet on Winning DuPont Analysis & Pick 4 Top Stocks

Zacks

2 years ago

Bet on Winning DuPont Analysis & Pick 4 Top Stocks

First Bancorp Inc's Dividend Analysis

GuruFocus.com

2 years ago

First Bancorp Inc's Dividend Analysis

Business Wire

2 years ago

The ONE Group Hospitality, Inc. to Participate in Two Upcoming Investor Conferences

Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc

GuruFocus.com

2 years ago

Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc

The ONE Group Hospitality Inc. Opens STK Salt Lake City

Business Wire

2 years ago

The ONE Group Hospitality Inc. Opens STK Salt Lake City

At US$8.09, Is Pangaea Logistics Solutions, Ltd. (NASDAQ:PANL) Worth Looking At Closely?

Simply Wall St.

2 years ago

At US$8.09, Is Pangaea Logistics Solutions, Ltd. (NASDAQ:PANL) Worth Looking At Closely?

Those who invested in Shoe Carnival (NASDAQ:SCVL) five years ago are up 79%

Simply Wall St.

2 years ago

Those who invested in Shoe Carnival (NASDAQ:SCVL) five years ago are up 79%

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

GlobeNewswire

2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Simply Wall St.

2 years ago

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Norwood Financial Corp Increases Cash Dividend

GlobeNewswire

2 years ago

Norwood Financial Corp Increases Cash Dividend

John Marshall Bank Hires Christopher Mullings as Senior Vice President, Commercial Team Lead in Arlington Region

Business Wire

2 years ago

John Marshall Bank Hires Christopher Mullings as Senior Vice President, Commercial Team Lead in Arlington Region

Outset Medical to Present at BofA Home Care Conference

Business Wire

2 years ago

Outset Medical to Present at BofA Home Care Conference

5 Struggling Stocks to Buy at a Discount

Motley Fool

2 years ago

5 Struggling Stocks to Buy at a Discount

Natural Gas Services Group, Inc. (NYSE:NGS) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Natural Gas Services Group, Inc. (NYSE:NGS) Q3 2023 Earnings Call Transcript

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

GlobeNewswire

2 years ago

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

Escalade (NASDAQ:ESCA) Might Be Having Difficulty Using Its Capital Effectively

Simply Wall St.

2 years ago

Escalade (NASDAQ:ESCA) Might Be Having Difficulty Using Its Capital Effectively

Implied Volatility Surging for On OPAL Fuels (OPAL) Stock Options

Zacks

2 years ago

Implied Volatility Surging for On OPAL Fuels (OPAL) Stock Options

GuruFocus.com

2 years ago

OPAL Fuels Inc (OPAL) Reports Mixed Q3 2023 Results Amidst Strategic Growth

OPAL Fuels Reports Third Quarter 2023 Results

Business Wire

2 years ago

OPAL Fuels Reports Third Quarter 2023 Results

5 Risky Stocks to Buy Immediately, According to AI

InvestorPlace

2 years ago

5 Risky Stocks to Buy Immediately, According to AI

IO Biotech Announces 2023 Third Quarter Results

GlobeNewswire

2 years ago

IO Biotech Announces 2023 Third Quarter Results

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

GlobeNewswire

2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

GlobeNewswire

2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Why Earnings Season Could Be Great for OPAL Fuels (OPAL)

Zacks

2 years ago

Why Earnings Season Could Be Great for OPAL Fuels (OPAL)

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire

2 years ago

IO Biotech Announces Participation in Upcoming Investor Conferences

The Zacks Analyst Blog Highlights NextEra Energy Partners, FREYR Battery, Enlight Renewable Energy, TC Energy and OPAL Fuels

Zacks

2 years ago

The Zacks Analyst Blog Highlights NextEra Energy Partners, FREYR Battery, Enlight Renewable Energy, TC Energy and OPAL Fuels

Nkarta to Participate at Upcoming Investor Conferences

GlobeNewswire

2 years ago

Nkarta to Participate at Upcoming Investor Conferences

This IO Biotech Insider Increased Their Holding In The Last Year

Simply Wall St.

2 years ago

This IO Biotech Insider Increased Their Holding In The Last Year

Analysts Estimate AFC Gamma Inc. (AFCG) to Report a Decline in Earnings: What to Look Out for

Zacks

2 years ago

Analysts Estimate AFC Gamma Inc. (AFCG) to Report a Decline in Earnings: What to Look Out for

PCB Bancorp (NASDAQ:PCB) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Simply Wall St.

2 years ago

PCB Bancorp (NASDAQ:PCB) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Share on Social Networks: